SlideShare ist ein Scribd-Unternehmen logo
1 von 26
Integrating Pharmacovigilance Into Quality Management System First Annual CAPA Congress Boris Videlov
Disclosure ,[object Object],[object Object]
Why have a Pharmacovigilance QMS? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Pharmacovigilance Process
Monitoring Metrics Reports ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Metrics Examples
Considerations for QMS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Electronic System(s) Selection ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Potential Challenges ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Likely Customization and Enhancements ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Identification of Quality & Compliance Issues ,[object Object],[object Object]
Quality Management of Document Review ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Quality Management of Contracting ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Quality Management of In- and Out-licensing ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Quality and Compliance of CT Data (slide 1 of 2) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Quality and Compliance of CT Data (slide 2 of 2) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Compliance and Quality Monitoring of Business Partners ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Compliance with Company AE Reporting Policy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Compliance Management of Expedited ICSRs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Compliance and Quality Management of Aggregate Reports ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Quality Management of ICSRs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Retrospective Quality Review ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Quality Management of the Signaling Process ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Quality Management of Inspections/Audits Records ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Quality Management of Data Verification ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Thank you for your attention! www.LinkedIn.com

Weitere ähnliche Inhalte

Was ist angesagt?

Post marketing surveilance
Post marketing surveilancePost marketing surveilance
Post marketing surveilanceaiswarya thomas
 
FDA Regulation of Drug and Device Advertising and Promotion -- The Basics
FDA Regulation of Drug and Device Advertising and Promotion -- The BasicsFDA Regulation of Drug and Device Advertising and Promotion -- The Basics
FDA Regulation of Drug and Device Advertising and Promotion -- The BasicsMichael Swit
 
Ind content & format of an ind application
Ind content & format of an ind applicationInd content & format of an ind application
Ind content & format of an ind applicationSandeshPattanaik
 
Europe CE Marking for medical devices under new MDR
Europe CE Marking for medical devices under new MDREurope CE Marking for medical devices under new MDR
Europe CE Marking for medical devices under new MDREMERGO
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Aakashdeep Raval
 
Compensation in clinical trial
Compensation in clinical trialCompensation in clinical trial
Compensation in clinical trialBhaumik Bavishi
 
Presentation: Hints and Tips for Acceptance of your Prescription Medicines Su...
Presentation: Hints and Tips for Acceptance of your Prescription Medicines Su...Presentation: Hints and Tips for Acceptance of your Prescription Medicines Su...
Presentation: Hints and Tips for Acceptance of your Prescription Medicines Su...TGA Australia
 
21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTS
21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTS21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTS
21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTSPallavi Christeen
 
Regulatory Highlights and Drug Development in China
Regulatory Highlights and Drug Development in ChinaRegulatory Highlights and Drug Development in China
Regulatory Highlights and Drug Development in ChinaMedpace
 
drug registrastion requirements in china ...sonali mishra
drug registrastion requirements in china  ...sonali mishradrug registrastion requirements in china  ...sonali mishra
drug registrastion requirements in china ...sonali mishraSonaliMishra64
 
Working with Argus Safety in a Global Community
Working with Argus Safety in a Global CommunityWorking with Argus Safety in a Global Community
Working with Argus Safety in a Global CommunityPerficient
 
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...Mohamed Fazil M
 
Periodic safety update reports – gvp guidelines and changes
Periodic safety update reports – gvp guidelines and changesPeriodic safety update reports – gvp guidelines and changes
Periodic safety update reports – gvp guidelines and changesTuracoz Healthcare Solutions
 
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...Until ROI
 
Identifying Safety Signals by Data Mining the FDA Adverse Event Reporting Sys...
Identifying Safety Signals by Data Mining the FDA Adverse Event Reporting Sys...Identifying Safety Signals by Data Mining the FDA Adverse Event Reporting Sys...
Identifying Safety Signals by Data Mining the FDA Adverse Event Reporting Sys...Perficient, Inc.
 
Clinical Research Regulation in European Union
Clinical Research Regulation in European Union Clinical Research Regulation in European Union
Clinical Research Regulation in European Union ShantanuThakre3
 

Was ist angesagt? (20)

Post marketing surveilance
Post marketing surveilancePost marketing surveilance
Post marketing surveilance
 
FDA Regulation of Drug and Device Advertising and Promotion -- The Basics
FDA Regulation of Drug and Device Advertising and Promotion -- The BasicsFDA Regulation of Drug and Device Advertising and Promotion -- The Basics
FDA Regulation of Drug and Device Advertising and Promotion -- The Basics
 
Ind content & format of an ind application
Ind content & format of an ind applicationInd content & format of an ind application
Ind content & format of an ind application
 
Europe CE Marking for medical devices under new MDR
Europe CE Marking for medical devices under new MDREurope CE Marking for medical devices under new MDR
Europe CE Marking for medical devices under new MDR
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.
 
Compensation in clinical trial
Compensation in clinical trialCompensation in clinical trial
Compensation in clinical trial
 
Fundamentals of Health Economics and Outcomes Research (HEOR)
Fundamentals of Health Economics and Outcomes Research (HEOR)Fundamentals of Health Economics and Outcomes Research (HEOR)
Fundamentals of Health Economics and Outcomes Research (HEOR)
 
Presentation: Hints and Tips for Acceptance of your Prescription Medicines Su...
Presentation: Hints and Tips for Acceptance of your Prescription Medicines Su...Presentation: Hints and Tips for Acceptance of your Prescription Medicines Su...
Presentation: Hints and Tips for Acceptance of your Prescription Medicines Su...
 
21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTS
21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTS21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTS
21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTS
 
Regulatory Highlights and Drug Development in China
Regulatory Highlights and Drug Development in ChinaRegulatory Highlights and Drug Development in China
Regulatory Highlights and Drug Development in China
 
drug registrastion requirements in china ...sonali mishra
drug registrastion requirements in china  ...sonali mishradrug registrastion requirements in china  ...sonali mishra
drug registrastion requirements in china ...sonali mishra
 
PSUR
PSURPSUR
PSUR
 
Working with Argus Safety in a Global Community
Working with Argus Safety in a Global CommunityWorking with Argus Safety in a Global Community
Working with Argus Safety in a Global Community
 
Regulatory requirements for orphan drugs delivery
Regulatory requirements for orphan drugs deliveryRegulatory requirements for orphan drugs delivery
Regulatory requirements for orphan drugs delivery
 
SAE resporting for case 005
SAE resporting for case 005SAE resporting for case 005
SAE resporting for case 005
 
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...
CDSCO Biologicals - Rules, Regulations, Guidelines and Standards for Regulato...
 
Periodic safety update reports – gvp guidelines and changes
Periodic safety update reports – gvp guidelines and changesPeriodic safety update reports – gvp guidelines and changes
Periodic safety update reports – gvp guidelines and changes
 
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...
 
Identifying Safety Signals by Data Mining the FDA Adverse Event Reporting Sys...
Identifying Safety Signals by Data Mining the FDA Adverse Event Reporting Sys...Identifying Safety Signals by Data Mining the FDA Adverse Event Reporting Sys...
Identifying Safety Signals by Data Mining the FDA Adverse Event Reporting Sys...
 
Clinical Research Regulation in European Union
Clinical Research Regulation in European Union Clinical Research Regulation in European Union
Clinical Research Regulation in European Union
 

Ähnlich wie FDA News Presentation

Clinical Data Management
Clinical Data ManagementClinical Data Management
Clinical Data ManagementDABBETA DIVYA
 
eTMF in the fast lane
eTMF in the fast laneeTMF in the fast lane
eTMF in the fast lanedirkbeth
 
Audit in Pharmacovigilance
Audit in PharmacovigilanceAudit in Pharmacovigilance
Audit in Pharmacovigilanceclarityeye
 
20080208 Dia Edm Maximizing Metadata Oberhofer
20080208 Dia Edm Maximizing Metadata Oberhofer20080208 Dia Edm Maximizing Metadata Oberhofer
20080208 Dia Edm Maximizing Metadata Oberhoferoberhofer
 
Continuous Auditing
Continuous AuditingContinuous Auditing
Continuous AuditingTianli Xie
 
Gamp Riskbased Approch To Validation
Gamp Riskbased Approch To ValidationGamp Riskbased Approch To Validation
Gamp Riskbased Approch To ValidationRajendra Sadare
 
Revelatory Trends in Clinical Research and Data Management
Revelatory Trends in Clinical Research and Data ManagementRevelatory Trends in Clinical Research and Data Management
Revelatory Trends in Clinical Research and Data ManagementSagar Ghotekar
 
FDA Update: Inspections, Observations and Metrics - OMTEC 2017
FDA Update: Inspections, Observations and Metrics - OMTEC 2017FDA Update: Inspections, Observations and Metrics - OMTEC 2017
FDA Update: Inspections, Observations and Metrics - OMTEC 2017April Bright
 
Learning technologies 2014: The Trickle Down Effect of Compliance
Learning technologies 2014: The Trickle Down Effect of ComplianceLearning technologies 2014: The Trickle Down Effect of Compliance
Learning technologies 2014: The Trickle Down Effect of ComplianceNetDimensions
 
QMS for Medical Devices.pptx
QMS for Medical Devices.pptxQMS for Medical Devices.pptx
QMS for Medical Devices.pptxPlavAnan
 
Generis Company Presentation for RIM
Generis Company Presentation for RIMGeneris Company Presentation for RIM
Generis Company Presentation for RIMGeneris
 
Clinicaldatamanagementindiaasahub 130313225150-phpapp01
Clinicaldatamanagementindiaasahub 130313225150-phpapp01Clinicaldatamanagementindiaasahub 130313225150-phpapp01
Clinicaldatamanagementindiaasahub 130313225150-phpapp01Upendra Agarwal
 
Webinar: How to Ace Your SaaS-based EDC System Validation for Sponsors and CROs
Webinar: How to Ace Your SaaS-based EDC System Validation for Sponsors and CROsWebinar: How to Ace Your SaaS-based EDC System Validation for Sponsors and CROs
Webinar: How to Ace Your SaaS-based EDC System Validation for Sponsors and CROsStatistics & Data Corporation
 

Ähnlich wie FDA News Presentation (20)

MAGI Presentation
MAGI PresentationMAGI Presentation
MAGI Presentation
 
Clinical Data Management
Clinical Data ManagementClinical Data Management
Clinical Data Management
 
System checkup
System checkupSystem checkup
System checkup
 
eTMF in the fast lane
eTMF in the fast laneeTMF in the fast lane
eTMF in the fast lane
 
Etmf in the fast lane
Etmf in the fast laneEtmf in the fast lane
Etmf in the fast lane
 
QMS at the Site
QMS at the SiteQMS at the Site
QMS at the Site
 
Audit in Pharmacovigilance
Audit in PharmacovigilanceAudit in Pharmacovigilance
Audit in Pharmacovigilance
 
Security audit
Security auditSecurity audit
Security audit
 
20080208 Dia Edm Maximizing Metadata Oberhofer
20080208 Dia Edm Maximizing Metadata Oberhofer20080208 Dia Edm Maximizing Metadata Oberhofer
20080208 Dia Edm Maximizing Metadata Oberhofer
 
Continuous Auditing
Continuous AuditingContinuous Auditing
Continuous Auditing
 
Gamp Riskbased Approch To Validation
Gamp Riskbased Approch To ValidationGamp Riskbased Approch To Validation
Gamp Riskbased Approch To Validation
 
Revelatory Trends in Clinical Research and Data Management
Revelatory Trends in Clinical Research and Data ManagementRevelatory Trends in Clinical Research and Data Management
Revelatory Trends in Clinical Research and Data Management
 
FDA Update: Inspections, Observations and Metrics - OMTEC 2017
FDA Update: Inspections, Observations and Metrics - OMTEC 2017FDA Update: Inspections, Observations and Metrics - OMTEC 2017
FDA Update: Inspections, Observations and Metrics - OMTEC 2017
 
Delta GMP Data Integrity Sept2016
Delta GMP Data Integrity Sept2016Delta GMP Data Integrity Sept2016
Delta GMP Data Integrity Sept2016
 
Learning technologies 2014: The Trickle Down Effect of Compliance
Learning technologies 2014: The Trickle Down Effect of ComplianceLearning technologies 2014: The Trickle Down Effect of Compliance
Learning technologies 2014: The Trickle Down Effect of Compliance
 
Capa ‘Bellwether’
Capa ‘Bellwether’Capa ‘Bellwether’
Capa ‘Bellwether’
 
QMS for Medical Devices.pptx
QMS for Medical Devices.pptxQMS for Medical Devices.pptx
QMS for Medical Devices.pptx
 
Generis Company Presentation for RIM
Generis Company Presentation for RIMGeneris Company Presentation for RIM
Generis Company Presentation for RIM
 
Clinicaldatamanagementindiaasahub 130313225150-phpapp01
Clinicaldatamanagementindiaasahub 130313225150-phpapp01Clinicaldatamanagementindiaasahub 130313225150-phpapp01
Clinicaldatamanagementindiaasahub 130313225150-phpapp01
 
Webinar: How to Ace Your SaaS-based EDC System Validation for Sponsors and CROs
Webinar: How to Ace Your SaaS-based EDC System Validation for Sponsors and CROsWebinar: How to Ace Your SaaS-based EDC System Validation for Sponsors and CROs
Webinar: How to Ace Your SaaS-based EDC System Validation for Sponsors and CROs
 

FDA News Presentation

Hinweis der Redaktion

  1. Good Morning My name is Boris Videlov, and I am responsible for all quality and compliance-related activities in the Global Drug Safety Department of Forest Research Institute. I will share with you today my views on what constitutes a QMS for Pharmacovigilance and some practical considerations on how to get there. Will provide information on SOME of the key elements of a Pharmacovigillance Quality management System and how to build it.
  2. FDA: CFR 21 Part 820, 211 Quality System Inspection Technique (QSIT) BARQA - British Association of Research Quality Assurance ASQ - American Society for Quality ISO 9001:2000
  3. Our metrics are our canaries in the coal mine. However, we need to be able to read our metrics. In the example here, there is a huge difference if the canary’s legs are pointing up - the course of action would be keep digging or “Run!”.
  4. When I was working on the presentation I was thinking how to depict our process, and this is what I came up with. Apologize to the vegetarians, it can be used as a vegie-grinder.
  5. Not to be tracked in QMS Subject to regulatory Audits Be mindful of the Regulatory Clock Start Date Compliance with applicable regulations Timeframes to respond to compliance issues – some difficulties Audit Clause - some difficulties Escalation/Penalties - some difficulties from Corporate/Legal Consider using a Contract Management tool Maintain key timeframes reference document/report
  6. # of queries Completion of SAE form Discrepancies between the CRF and SAE form
  7. # of queries SAE Form completeness and accuracy – Quality review of samle Discrepancies between the CRF and SAE form
  8. Signal confirmation Preplanned CAPA, such as labeling changes, “black box” warning, up to withdrawal from the market.
  9. Inspections & Audits are a important and highly visible source of quality records and most often company-wide CAPA. We always speak about Inspection readiness, but are we always ready? Anything said in Latin sounds profound